HalioDx said that Chinese oncologists will gain access to its Immunoscore assay for predicting the risk of recurrence of early-stage colon cancer.
Research presented at ACMG by Invitae suggests that clinically actionable variants in cancer patients are missed by germline testing that is not done with expanded panels.
As of January the project had returned 290 positive results for CDC Tier 1 conditions from 23,500 participants who had undergone exome sequencing.
The center received a response to its initial submission to the NY State Department of Health in February and will re-submit by the end of this month.
Clinical researchers at AACR discussed a wide range of approaches focusing on several different potential use-cases in the detection or assessment of early cancers.
The company presented new data on the performance of a multi-pronged liquid biopsy assay in detecting colorectal cancers across a range of clinical stages.
VolitionRx's platform uses the company's Nucleosomics technology for identifying and quantifying nucleosome structural features such as histone modifications.
The firms plan to use Natera's cell-free DNA liquid biopsy assay to monitor patients' response to Amal's cancer vaccine in combination with immunotherapy.
For the Evry, France-based company, the grant will support its vision of making its technology available as a platform for running oncology assays.
Epigenomics terminated a licensing contract related to Chinese distribution rights for its Septin9 biomarker and Epi proColon colorectal cancer blood test.